4.6 Article

Acute Lung Functional and Airway Remodeling Effects of an Inhaled Highly Selective Phosphodiesterase 4 Inhibitor in Ventilated Preterm Lambs Exposed to Chorioamnionitis

Journal

PHARMACEUTICALS
Volume 16, Issue 1, Pages -

Publisher

MDPI
DOI: 10.3390/ph16010029

Keywords

PDE inhibitors; neonatal lung injury; respiratory distress syndrome; bronchopulmonary dysplasia

Ask authors/readers for more resources

Phosphodiesterase (PDE) inhibition has been explored as a potential treatment for neonatal lung injury, but our study found that high doses of the inhaled PDE4 inhibitor GSK256066 can have detrimental effects and promote lung inflammation. We investigated the effects of high and low doses of GSK256066 on lung function and development, and found that high doses impaired oxygenation and altered alveologenesis in the premature lung. Our findings suggest a narrow therapeutic window for PDE4 inhibitors in the developing lung.
Phosphodiesterase (PDE) inhibition has been identified in animal studies as a new treatment option for neonatal lung injury, and as potentially beneficial for early lung development and function. However, our group could show that the inhaled PDE4 inhibitor GSK256066 could have dose-dependent detrimental effects and promote lung inflammation in the premature lung. In this study, the effects of a high and a low dose of GSK256066 on lung function, structure and alveolar development were investigated. In a triple hit lamb model of Ureaplasma-induced chorioamnionitis, prematurity, and mechanical ventilation, 21 animals were treated as unventilated (NOVENT) or 24 h ventilated controls (Control), or with combined 24 h ventilation and low dose (iPDE1) or high dose (iPDE10) treatment with inhaled GSK 256066. We found that high doses of an inhaled PDE4 inhibitor impaired oxygenation during mechanical ventilation. In this group, the budding of secondary septae appeared to be decreased in the preterm lung, suggesting altered alveologenesis. Ventilation-induced structural and functional changes were only modestly ameliorated by a low dose of PDE4 inhibitor. In conclusion, our findings indicate the narrow therapeutic window of PDE4 inhibitors in the developing lung.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available